2016
DOI: 10.1373/clinchem.2015.245027
|View full text |Cite
|
Sign up to set email alerts
|

Your Viral Past: A Comprehensive Method for Serological Profiling to Explore the Human Virome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

2
0
0

Year Published

2018
2018
2019
2019

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 4 publications
2
0
0
Order By: Relevance
“…These public epitopes could be further validated using specimens with acute infections or using longitudinal studies to determine if these epitopes appear upon vaccination [56]. We did not find epitopes corresponding to measles or rubella vaccination, which is consistent with a recent study that comprehensively identified viral epitopes [57]. This implies that for these viruses, high titer antibodies targeting linear epitopes may not be present.…”
Section: Discussionsupporting
confidence: 85%
“…These public epitopes could be further validated using specimens with acute infections or using longitudinal studies to determine if these epitopes appear upon vaccination [56]. We did not find epitopes corresponding to measles or rubella vaccination, which is consistent with a recent study that comprehensively identified viral epitopes [57]. This implies that for these viruses, high titer antibodies targeting linear epitopes may not be present.…”
Section: Discussionsupporting
confidence: 85%
“…These public epitopes could be further validated using specimens with acute infections or using longitudinal studies to determine if these epitopes appear upon vaccination [61]. We did not find epitopes corresponding to measles or rubella vaccination, which is consistent with a recent study that comprehensively predicted viral epitopes [62]. This implies that for these viruses, high titer antibodies targeting linear epitopes may not be present.…”
Section: Discussionsupporting
confidence: 85%